Antimalarial Drug Artemisinin Extenuates Amyloidogenesis and Neuroinflammation in APP swe/PS 1dE9 Transgenic Mice via Inhibition of Nuclear Factor‐κ B and NLRP 3 Inflammasome Activation
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Summary: Background: The activation of nuclear factor‐kappa B (NF‐κB) and NLRP 3 inflammasome is involved in neuroinflammation, which is closely linked to A lzheimer's disease (AD). In vivo and in vitro studies have suggested that artemisinin shows antiinflammatory effects in inflammation‐related diseases. However, the impacts of artemisinin on AD have not been investigated. Aims: In this study, 5‐month‐old APP swe/PS 1dE9 transgenic mice were treated daily with 40 mg/kg artemisinin for 30 days by intraperitoneal injection to evaluate the effects of artemisinin on AD. Results: We found that artemisinin treatment (1) decreased neuritic plaque burden; (2) did not alter Aβ transport across the blood–brain barrier; (3) regulated APP processing via inhibiting β‐secretase activity; (4) inhibited NF‐κB activity and NALP 3 inflammasome activation in APP swe/PS 1dE9 double transgenic mice. Conclusions: The in vivo study clearly demonstrates that artemisinin has protective effects on AD pathology due to its effects on suppressing NF‐κB activity and NALP 3 inflammasome activation. Our study suggests that targeting NF‐κB activity and NALP 3 inflammasome activation offers a valuable intervention for AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NLRP3 is activated in Alzheimer’s disease and contributes to pathology in APP/PS1 mice
Heneka, M. T., Kummer, M. P., Stutz, A., Delekate, A., Schwartz, S., Vieira-Saecker, A., Griep, A., Axt, D., Remus, A., Tzeng, T.-C., et al. (2013) · Nature · doi:10.1038/nature11729 · Cited by 2,898
The NALP3 inflammasome is involved in the innate immune response to amyloid-β
Halle, A., Hornung, V., Petzold, G. C., Stewart, C. R., Monks, B. G., Reinheckel, T., Fitzgerald, K. A., Latz, E., Moore, K. J., & Golenbock, D. T. (2008) · Nature Immunology · doi:10.1038/ni.1636 · Cited by 2,441
Decreased Clearance of CNS β-Amyloid in Alzheimer’s Disease
Mawuenyega, K. G., Sigurdson, W., Ovod, V., Munsell, L., Kasten, T., Morris, J. C., Yarasheski, K. E., & Bateman, R. J. (2010) · Science · doi:10.1126/science.1197623 · Cited by 2,078
Amyloid Precursor Protein Processing and Alzheimer's Disease
O'Brien, R. J., & Wong, P. C. (2011) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-061010-113613 · Cited by 2,061 · cited 1×
“Ab is released from amyloid precursor protein by the action of b-secretase and c-secretase, which have been regarded as therapeutic targets for AD [2].”
BackgroundJankowsky, J. L., Fadale, D. J., Anderson, J., Xu, G. M., Gonzales, V., Jenkins, N. A., Copeland, N. G., Lee, M. K., Younkin, L. H., Wagner, S. L., et al. (2004) · Human Molecular Genetics · doi:10.1093/hmg/ddh019 · Cited by 1,575
Nonsteroidal Antiinflammatory Drugs and the Risk of Alzheimer's Disease
in 't Veld, B. A., Ruitenberg, A., Hofman, A., Launer, L. J., van Duijn, C. M., Stijnen, T., Breteler, M. M. B., & Stricker, B. H. C. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010178 · Cited by 1,196
Inflammation in Alzheimer Disease--A Brief Review of the Basic Science and Clinical Literature
Wyss-Coray, T., & Rogers, J. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006346 · Cited by 975 · cited 1×
“In basic and clinical studies, inflammation has been demonstrated to be involved in the pathogenesis and progress of AD [3].”
BackgroundChen, C.-H., Zhou, W., Liu, S., Deng, Y., Cai, F., Tone, M., Tone, Y., Tong, Y., & Song, W. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711000149 · Cited by 433
Deane, R., Wu, Z., & Zlokovic, B. V. (2004) · Stroke · doi:10.1161/01.str.0000143452.85382.d1 · Cited by 392
He, P., Zhong, Z., Lindholm, K., Berning, L., Lee, W., Lemere, C., Staufenbiel, M., Li, R., & Shen, Y. (2007) · The Journal of Cell Biology · doi:10.1083/jcb.200705042 · Cited by 390
Sehgal, N., Gupta, A., Valli, R. K., Joshi, S. D., Mills, J. T., Hamel, E., Khanna, P., Jain, S. C., Thakur, S. S., & Ravindranath, V. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1112209109 · Cited by 390
Shi, J.-Q., Shen, W., Chen, J., Wang, B.-R., Zhong, L.-L., Zhu, Y.-W., Zhu, H.-Q., Zhang, Q.-Q., Zhang, Y.-D., & Xu, J. (2011) · Brain Research · doi:10.1016/j.brainres.2010.10.053 · Cited by 219
Self-citationInhibition of Aβ production by NF-κB inhibitors
Paris, D., Patel, N., Quadros, A., Linan, M., Bakshi, P., Ait-Ghezala, G., & Mullan, M. (2007) · Neuroscience Letters · doi:10.1016/j.neulet.2006.12.029 · Cited by 75
MyD88 Deficiency Ameliorates β-Amyloidosis in an Animal Model of Alzheimer's Disease
Lim, J.-E., Kou, J., Song, M., Pattanayak, A., Jin, J., Lalonde, R., & Fukuchi, K.-I. (2011) · The American Journal of Pathology · doi:10.1016/j.ajpath.2011.05.045 · Cited by 63
Research works printed but not linked: 31
- 10.1001/jama.287.18.2335 · DOI · Paper page
- 10.3233/JAD-2009-0976 · DOI · Paper page
- 10.1002/jnr.21252 · DOI · Paper page
- 10.4049/jimmunol.0901363 · DOI · Paper page
- 10.1111/j.1582-4934.2008.00496.x · DOI · Paper page
- 10.1155/2012/247597 · DOI · Paper page
- 10.1016/j.ejphar.2010.09.018 · DOI
- 10.3892/ijmm.2010.580 · DOI
- 10.1371/journal.pone.0035125 · DOI · Paper page
- 10.1620/tjem.227.161 · DOI
- 10.1093/abbs/gmq101 · DOI
- 10.4049/jimmunol.179.9.5958 · DOI
- 10.4061/2011/517160 · DOI · Paper page
- 10.1186/1742-2094-9-99 · DOI · Paper page
- 10.1084/jem.20081588 · DOI · Paper page
- 10.1073/pnas.0500972102 · DOI · Paper page
- 10.2174/156720512800492549 · DOI · Paper page
- 10.1212/WNL.59.6.880 · DOI · Paper page
- 10.1016/S0165-5728(97)00054-4 · DOI
- 10.1002/jnr.21548 · DOI · Paper page
- 10.1007/s11064-011-0532-0 · DOI
- 10.1016/j.ejphar.2011.09.019 · DOI
- 10.1016/j.neuint.2011.11.005 · DOI
- 10.1186/1742-2094-9-35 · DOI · Paper page
- 10.1111/j.1471-4159.2011.07642.x · DOI · Paper page
- 10.1074/jbc.M111.333054 · DOI · Paper page
- 10.1111/j.1755-5949.2012.00341.x · DOI
- 10.1186/1742-2094-7-17 · DOI · Paper page
- 10.2174/187152709787601867 · DOI · Paper page
- 10.1016/j.neurobiolaging.2010.05.026 · DOI · Paper page
- 10.1021/jf051985c · DOI · Paper page
Cited by
Artemisinins: Pharmacological actions beyond anti-malarial
Ho, W. E., Peh, H. Y., Chan, T. K., & Wong, W. S. F. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.12.001 · Cited by 481
NLRP3 inflammasome in neurological diseases, from functions to therapies
Song, L., Pei, L., Yao, S., Wu, Y., & Shang, Y. (2017) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2017.00063 · Cited by 467
The effects of microglia-associated neuroinflammation on Alzheimer’s disease
Wang, C., Zong, S., Cui, X., Wang, X., Wu, S., Wang, L., Liu, Y., & Lu, Z. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1117172 · Cited by 298
Microglia in Alzheimer’s disease: pathogenesis, mechanisms, and therapeutic potentials
Miao, J., Ma, H., Yang, Y., Liao, Y., Lin, C., Zheng, J., Yu, M., & Lan, J. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1201982 · Cited by 293
Focus on the Role of NLRP3 Inflammasome in Diseases
Fusco, R., Siracusa, R., Genovese, T., Cuzzocrea, S., & Di Paola, R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124223 · Cited by 290
Metadata
- Authors
- Shi, J., Zhang, C., Sun, X., Cheng, X., Wang, J., Zhang, Y., Xu, J., & Zou, H.
- Venue
- CNS Neuroscience & Therapeutics
- Publisher
- Wiley
- Published
- 2013-02-14
- Volume
- 19
- Issue
- 4
- Pages
- 262-268
- ISSN
- 1755-5930 (ISSN-L)
- 1755-5949
- OpenAlex
- W2060001014
- Cited by
- 115
- References
- 14
- FWCI
- 5.10
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.